{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T01:02:13Z","timestamp":1775005333125,"version":"3.50.1"},"reference-count":82,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Neoadjuvant chemotherapy (NACT) for certain breast cancer (BC) subtypes confers significant tumor regression rates and a survival benefit for patients with a complete pathologic response. Clinical and preclinical studies have demonstrated that immune-related factors are responsible for better treatment outcomes, and thus, neoadjuvant immunotherapy (IO) has emerged as a means to further improve patient survival rates. Innate immunological \u201ccoldness\u201d, however, of specific BC subtypes, especially of the luminal ones, due to their immunosuppressive tumor microenvironment, hinders the efficacy of immune checkpoint inhibitors. Treatment policies aiming to reverse this immunological inertia are, therefore, needed. Moreover, radiotherapy (RT) has been proven to have a significant interplay with the immune system and promote anti-tumor immunity. This \u201cradiovaccination\u201d effect could be exploited in the neoadjuvant setting of BC and significantly enhance the effects of the already established clinical practice. Modern stereotactic irradiation techniques directed to the primary tumor and involved lymph nodes may prove important for the RT-NACT-IO combination. In this review, we provide an overview and critically discuss the biological rationale, clinical experience, and ongoing research underlying the interplay between neoadjuvant chemotherapy, anti-tumor immune response, and the emerging role of RT as a preoperative adjunct with immunological therapeutic implications in BC.<\/jats:p>","DOI":"10.3390\/ijms24119310","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T16:19:37Z","timestamp":1685204377000},"page":"9310","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anti-Tumor Immunity and Preoperative Radiovaccination: Emerging New Concepts in the Treatment of Breast Cancer"],"prefix":"10.3390","volume":"24","author":[{"given":"Ioannis M.","family":"Koukourakis","sequence":"first","affiliation":[{"name":"Radiation Oncology Unit, 1st Department of Radiology, Aretaieion University Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marios","family":"Papadimitriou","sequence":"additional","affiliation":[{"name":"Oncology Unit, Aretaieion University Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitra","family":"Desse","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, 1st Department of Radiology, Aretaieion University Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Zygogianni","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, 1st Department of Radiology, Aretaieion University Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8084-0445","authenticated-orcid":false,"given":"Christos","family":"Papadimitriou","sequence":"additional","affiliation":[{"name":"Oncology Unit, Aretaieion University Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"National Comprehensive Cancer Network (2022, November 26). Breast Cancer (Version 4.2022). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41571-022-00687-1","article-title":"Systemic therapy for early-stage breast cancer: Learning from the past to build the future","volume":"19","author":"Agostinetto","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","article-title":"Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18","volume":"15","author":"Fisher","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","article-title":"Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18","volume":"2001","author":"Wolmark","year":"2001","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1200\/JCO.2001.19.22.4224","article-title":"Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902","volume":"19","author":"Julien","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1200\/JCO.2005.05.078","article-title":"Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group","volume":"23","author":"Raab","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2008.19.2567","article-title":"Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer","volume":"27","author":"Gianni","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","article-title":"Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)","volume":"33","author":"Sikov","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial","volume":"15","author":"Schneeweiss","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e066381","DOI":"10.1136\/bmj-2021-066381","article-title":"Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: Systematic review and meta-analysis","volume":"375","author":"Conforti","year":"2021","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Jiang, T., Shi, W., Wali, V.B., Pongor, L.S., Li, C., Lau, R., Gy\u0151rffy, B., Lifton, R.P., Symmans, W.F., and Pusztai, L. (2016). Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002193"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bonnet, E., Haddad, V., Quesada, S., Baffert, K.-A., Lardy-Cl\u00e9aud, A., Treilleux, I., Pissaloux, D., Attignon, V., Wang, Q., and Buisson, A. (2022). Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial. J. Pers. Med., 12.","DOI":"10.3390\/jpm12101595"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"19107","DOI":"10.1038\/s41598-019-55710-w","article-title":"Molecular stratification within triple-negative breast cancer subtypes","volume":"9","author":"Wang","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Mao, Y., Qu, Q., Zhang, Y., Liu, J., Chen, X., and Shen, K. (2014). The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115103"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): A randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-022-06609-0","article-title":"Hypoxia and anaerobic metabolism relate with immunologically cold breast cancer and poor prognosis","volume":"194","author":"Giatromanolaki","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cmet.2018.04.022","article-title":"Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer","volume":"28","author":"Li","year":"2018","journal-title":"Cell Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1172\/JCI96268","article-title":"Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy","volume":"128","author":"Jayaprakash","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/COC.0000000000000691","article-title":"A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients with Advanced Solid Tumors","volume":"43","author":"McDonald","year":"2020","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-018-0360-8","article-title":"Targeting adenosine for cancer immunotherapy","volume":"6","author":"Leone","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"118389","DOI":"10.1016\/j.lfs.2020.118389","article-title":"Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways","volume":"259","author":"Giatromanolaki","year":"2020","journal-title":"Life Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102461","DOI":"10.1016\/j.ctrv.2022.102461","article-title":"Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy","volume":"110","author":"Fujiwara","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40425-017-0285-7","article-title":"Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer","volume":"5","author":"Mani","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Chen, C.L., Hsu, S.C., Ann, D.K., Yen, Y., and Kung, H.J. (2021). Arginine Signaling and Cancer Metabolism. Cancers, 13.","DOI":"10.3390\/cancers13143541"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e1316437","DOI":"10.1080\/2162402X.2017.1316437","article-title":"Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade","volume":"6","author":"Secondini","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1634\/theoncologist.11-4-342","article-title":"Chemotherapeutic approaches for targeting cell death pathways","volume":"11","author":"Ricci","year":"2006","journal-title":"Oncologist"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/s41419-020-03209-y","article-title":"Ionizing radiation results in a mixture of cellular outcomes including mitotic catastrophe, senescence, methuosis, and iron-dependent cell death","volume":"11","author":"Adjemian","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1703449","DOI":"10.1080\/2162402X.2019.1703449","article-title":"Trial watch: Chemotherapy-induced immunogenic cell death in immuno-oncology","volume":"9","author":"Vanmeerbeek","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Vaes, R.D.W., Hendriks, L.E.L., Vooijs, M., and De Ruysscher, D. (2021). Biomarkers of Radiotherapy-Induced Immunogenic Cell Death. Cells, 10.","DOI":"10.3390\/cells10040930"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kim, R., and Kin, T. (2021). Current and Future Therapies for Immunogenic Cell Death and Related Molecules to Potentially Cure Primary Breast Cancer. Cancers, 13.","DOI":"10.3390\/cancers13194756"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10495-019-01532-0","article-title":"Calreticulin in phagocytosis and cancer: Opposite roles in immune response outcomes","volume":"24","author":"Oldak","year":"2019","journal-title":"Apoptosis"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.it.2012.08.002","article-title":"Calreticulin in the immune system: Ins and outs","volume":"34","author":"Raghavan","year":"2013","journal-title":"Trends Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41419-022-04526-0","article-title":"Irradiation causes senescence, ATP release, and P2X7 receptor isoform switch in glioblastoma","volume":"13","author":"Zanoni","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.4049\/jimmunol.165.8.4704","article-title":"Extracellular ATP and TNF-alpha synergize in the activation and maturation of human dendritic cells","volume":"165","author":"Schnurr","year":"2000","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e001966","DOI":"10.1136\/jitc-2020-001966","article-title":"Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy","volume":"9","author":"Hubert","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13046-021-01962-2","article-title":"Interferon- and STING-independent induction of type I interferon stimulated genes during fractionated irradiation","volume":"40","author":"Goedegebuure","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/09553002.2023.2144960","article-title":"The molecular basis of immuno-radiotherapy","volume":"99","author":"Koukourakis","year":"2022","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/(SICI)1097-0215(19990730)82:3<385::AID-IJC12>3.0.CO;2-5","article-title":"Radiation-induced normal tissue injury: Role of adhesion molecules in leukocyte-endothelial cell interactions","volume":"82","author":"Quarmby","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","article-title":"Whole body irradiation; radiobiology or medicine?","volume":"26","author":"Mole","year":"1953","journal-title":"Br. J. Radiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4786819","DOI":"10.1155\/2018\/4786819","article-title":"The Evolution of Radiation Therapy in Metastatic Breast Cancer: From Local Therapy to Systemic Agent","volume":"2018","author":"Jutzy","year":"2018","journal-title":"Int. J. Breast Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Alard","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: The TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clbc.2020.01.012","article-title":"A Phase II Study of Pembrolizumab in Combination with Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer","volume":"20","author":"Krop","year":"2020","journal-title":"Clin. Breast Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41523-022-00404-2","article-title":"Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +\/\u2212 trastuzumab in patients with breast cancer brain metastases","volume":"8","author":"Page","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/cncr.32599","article-title":"A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer","volume":"126","author":"Ho","year":"2020","journal-title":"Cancer"},{"key":"ref_57","first-page":"359","article-title":"Effect of Preoperative Irradiation in Primary Operable Cancer of the Breast","volume":"35","author":"Adair","year":"1936","journal-title":"Am. J. Roentgenol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/1097-0142(197809)42:3<1120::AID-CNCR2820420313>3.0.CO;2-B","article-title":"Preoperative radiotherapy in operable breast cancer: Results in the Stockholm Breast Cancer Trial","volume":"42","author":"Wallgren","year":"1978","journal-title":"Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/oxfordjournals.annonc.a058929","article-title":"Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer","volume":"5","author":"Semiglazov","year":"1994","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.critrevonc.2014.04.005","article-title":"Primary systemic therapy and whole breast irradiation for locally advanced breast cancer: A systematic review","volume":"92","author":"Kuten","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.radonc.2012.01.008","article-title":"Effect of preoperative rescue concomitant FUN\/XUN-based chemo-radiotherapy for neoadjuvant chemotherapy-refractory breast cancer","volume":"103","author":"Bourgier","year":"2012","journal-title":"Radiother. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"24525","DOI":"10.18632\/oncotarget.24313","article-title":"Trends and outcomes of neoadjuvant radiotherapy compared with postoperative radiotherapy for malignant breast cancer","volume":"9","author":"Fu","year":"2018","journal-title":"Oncotarget"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"14288","DOI":"10.1038\/s41598-022-18251-3","article-title":"Survival comparison between postoperative and preoperative radiotherapy for stage I-III non-inflammatory breast cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/02841867509132679","article-title":"Effect of therapeutic radiation on peripheral blood lymphocytes in patients with carcinoma of the breast","volume":"14","author":"Jenkins","year":"1975","journal-title":"Acta Radiol. Ther. Phys. Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0009-9260(80)80183-8","article-title":"Recovery of lymphocyte status after radiotherapy","volume":"31","author":"Chamberlain","year":"1980","journal-title":"Clin. Radiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-018-05106-7","article-title":"Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer","volume":"174","author":"Patel","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"768956","DOI":"10.3389\/fonc.2022.768956","article-title":"Radiation Induced Lymphopenia Is Associated with the Effective Dose to the Circulating Immune Cells in Breast Cancer","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10552-020-01337-6","article-title":"Lymphopenia and clinical outcomes in patients with residual nodal disease after neoadjuvant chemotherapy for breast cancer","volume":"31","author":"Gutkin","year":"2020","journal-title":"Cancer Causes Control"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s12094-018-1851-2","article-title":"Comparative analysis of the effect of different radiotherapy regimes on lymphocyte and its subpopulations in breast cancer patients","volume":"20","author":"Yuan","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijrobp.2020.02.633","article-title":"Radiation-Induced Lymphopenia Predicts Poorer Prognosis in Patients with Breast Cancer: A Post Hoc Analysis of a Randomized Controlled Trial of Postmastectomy Hypofractionated Radiation Therapy","volume":"108","author":"Sun","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1245\/s10434-023-13233-9","article-title":"Preoperative Partial Breast Irradiation in Patients with Low-Risk Breast Cancer: A Systematic Review of Literature","volume":"30","author":"Civil","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e002038","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: One-size regimen does not fit all settings, so how does one choose?","volume":"9","author":"Demaria","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/cncr.33424","article-title":"Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety","volume":"127","author":"Williamson","year":"2021","journal-title":"Cancer"},{"key":"ref_74","unstructured":"(2023, January 05). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03366844."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"McArthur, H., Shiao, S., Karlan, S., Amersi, F., Arnold, B., Basho, R., Burnison, M., Chung, A., Chung, C., and Dang, C. (2019, January 10\u201314). Pre-operative pembrolizumab (pembro) with radiation therapy (RT) in patients with operable triple-negative breast cancer (TNBC) [abstract]. Proceedings of the 2019 San Antonio Breast Cancer Symposium, San Antonio, TX, USA. Cancer Res.2020, 80 (Suppl. 4), Abstract nr P3-09-09.","DOI":"10.1158\/1538-7445.SABCS19-P3-09-09"},{"key":"ref_76","unstructured":"(2023, January 05). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03804944."},{"key":"ref_77","unstructured":"(2023, January 05). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04443348."},{"key":"ref_78","unstructured":"(2023, January 05). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04454528."},{"key":"ref_79","unstructured":"(2023, January 05). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04807192."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e002484","DOI":"10.1136\/jitc-2021-002484","article-title":"Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist","volume":"9","author":"Sabree","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_81","unstructured":"(2023, January 05). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03875573."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.trecan.2016.01.003","article-title":"Anti-CD73 in cancer immunotherapy: Awakening new opportunities","volume":"2","author":"Antonioli","year":"2016","journal-title":"Trends Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/11\/9310\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:42:43Z","timestamp":1760125363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/11\/9310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":82,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ijms24119310"],"URL":"https:\/\/doi.org\/10.3390\/ijms24119310","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]}}}